Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 6 consecutive quarters of double digit growth.
Click here to learn more ›

Safety and Efficacy of Bremelanotide for HSDD in Women: RECONNECT Study Open-Label Extension Phase Results

Leave a Reply

Scroll to Top